Ray Therapeutics

Peter Francis, M.D., Ph.D., Chief Scientific and Medical Officer

April 12 | 9:30am | Dark Horse Consulting Ballroom 

San Francisco, CA


Ray Therapeutics (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting and will not require light-enhancing goggles. Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity, and visual field. Our lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world leading AAV gene therapy manufacturer and is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.


By using this website you agree to accept our Privacy Policy and Terms & Conditions